Michigan Medicine
Annual Hematologic
Malignancies Symposium
Saturday, October 19, 2024
7:30 am – 4:30 pm
Check in and continental breakfast at 7:00 am
THE KENSINGTON HOTEL
3500 SOUTH STATE STREET , ANN ARBOR, MICHIGAN 48108
The Speakers
Keynote Speaker
P. Leif Bergsagel, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Director, Mayo Clinic SPORE in Multiple Myeloma
Co-Director, Hematologic Malignancies Program Mayo Clinic Cancer Center
Division of Hematology, Mayo Clinic, Phoenix, AZ
David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Director, Mayo Clinic SPORE in Multiple Myeloma
Co-Director, Hematologic Malignancies Program Mayo Clinic Cancer Center
Division of Hematology, Mayo Clinic, Phoenix, AZ
Michigan Medicine
Division of Hematology Oncology
Michigan Medicine
Division of Hematology Oncology
Michigan Medicine
Molecular and Genomic Pathology
Michigan Medicine
Division of Hematology Oncology: Adult Blood and Marrow Transplantation
Michigan Medicine
Division of Hematology Oncology
City of Hope Comprehensive Cancer Center, Los Angeles, CA
Michigan Medicine
Division of Hematology Oncology
Michigan Medicine
Division of Hematology Oncology
Michigan Medicine
Division of Hematology Oncology;
Section Head, Lymphoma and Myeloma
Target Audience
This symposium is intended for physicians, physicians in training (residents/fellows), medical students, pharmacists, and advanced practice providers in the field of malignant hematology.
Description with expected results
The University of Michigan Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The UMRCC catchment area includes the entire State of Michigan, its ≈10M residents, and ≈750 community medical oncologists. After completing this activity participants will be able to utilize current, state of the art updates in the diagnosis, risk stratification, and treatment of all hematologic malignancies. They will also be able to enroll patients to the ground breaking and often lifesaving clinical trials. After completion of this activity, patient outcomes will be improved by having been enrolled in the appropriate clinical trials designed specifically to treat Hematologic Malignancies.
Faculty Planner
Ryan Wilcox, MD, PhD
Department of Internal Medicine,
Division of Hematology/Oncology
Section Head, Lymphoma & Myeloma
This symposium is intended for physicians, physicians in training (residents/fellows), medical students, pharmacists, and advanced practice providers in the field of malignant hematology.
Description with expected results
The University of Michigan Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The UMRCC catchment area includes the entire State of Michigan, its ≈10M residents, and ≈750 community medical oncologists. After completing this activity participants will be able to utilize current, state of the art updates in the diagnosis, risk stratification, and treatment of all hematologic malignancies. They will also be able to enroll patients to the ground breaking and often lifesaving clinical trials. After completion of this activity, patient outcomes will be improved by having been enrolled in the appropriate clinical trials designed specifically to treat Hematologic Malignancies.
Faculty Planner
Ryan Wilcox, MD, PhD
Department of Internal Medicine,
Division of Hematology/Oncology
Section Head, Lymphoma & Myeloma
Financial Disclosure Information
Individuals in control of content have no relevant financial relationships with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.